NTRA: חוב לטווח קצר של החברה Natera

Natera, Inc. optimizes reagent and equipment procurement to minimize supply risks. Total short-term liabilities help assess financial autonomy, with the most recent value recorded as 0.11. Stable demand for non-invasive diagnostics ensures a steady order flow, while strategic alliances in oncogenetics and the acquisition of molecular technologies create powerful synergies for business growth.

Natera, Inc. (NTRA) investments in recruiting leading bioinformaticians require strict control over short-term financial liabilities. This indicator aggregates all obligations due for settlement within the next operating cycle. The metric is calculated as the sum of current loans and accrued interest. A reduction in this volume confirms high capital liquidity, while a stable downward trend guarantees the company's resilience to market shocks.